NZ730012A - Compounds and compositions for modulating egfr mutant kinase activities - Google Patents
Compounds and compositions for modulating egfr mutant kinase activitiesInfo
- Publication number
- NZ730012A NZ730012A NZ730012A NZ73001215A NZ730012A NZ 730012 A NZ730012 A NZ 730012A NZ 730012 A NZ730012 A NZ 730012A NZ 73001215 A NZ73001215 A NZ 73001215A NZ 730012 A NZ730012 A NZ 730012A
- Authority
- NZ
- New Zealand
- Prior art keywords
- provides
- protein kinase
- present
- compositions
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quick-Acting Or Multi-Walled Pipe Joints (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063394P | 2014-10-13 | 2014-10-13 | |
| PCT/KR2015/010784 WO2016060443A2 (en) | 2014-10-13 | 2015-10-13 | Compounds and compositions for modulating egfr mutant kinase activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ730012A true NZ730012A (en) | 2019-06-28 |
Family
ID=55654993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ730012A NZ730012A (en) | 2014-10-13 | 2015-10-13 | Compounds and compositions for modulating egfr mutant kinase activities |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9593098B2 (enExample) |
| EP (5) | EP3929190B1 (enExample) |
| JP (3) | JP6524221B2 (enExample) |
| KR (5) | KR20240074820A (enExample) |
| CN (2) | CN111686110B (enExample) |
| AU (1) | AU2015331166B2 (enExample) |
| BR (1) | BR112017007769B1 (enExample) |
| CA (1) | CA2962914C (enExample) |
| CY (3) | CY1122737T1 (enExample) |
| DK (4) | DK4421069T3 (enExample) |
| ES (4) | ES2770058T3 (enExample) |
| FI (3) | FI3929190T3 (enExample) |
| FR (1) | FR25C1021I2 (enExample) |
| HR (4) | HRP20250213T1 (enExample) |
| HU (4) | HUE054848T2 (enExample) |
| LT (5) | LT4421069T (enExample) |
| MX (3) | MX385942B (enExample) |
| NL (1) | NL301329I2 (enExample) |
| NO (1) | NO2025025I1 (enExample) |
| NZ (1) | NZ730012A (enExample) |
| PH (1) | PH12017500488A1 (enExample) |
| PL (4) | PL4421069T3 (enExample) |
| PT (4) | PT3604294T (enExample) |
| RS (4) | RS67623B1 (enExample) |
| RU (1) | RU2727700C2 (enExample) |
| SG (1) | SG11201701960XA (enExample) |
| SI (4) | SI3929190T1 (enExample) |
| SM (4) | SMT202100266T1 (enExample) |
| TW (2) | TWI730331B (enExample) |
| WO (1) | WO2016060443A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054848T2 (hu) * | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| MX383920B (es) * | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| KR102030886B1 (ko) * | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| JP7028900B2 (ja) * | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
| WO2019022486A1 (en) * | 2017-07-28 | 2019-01-31 | Yuhan Corporation | NOVEL INTERMEDIATES USEFUL FOR SYNTHESIZING AMINOPYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PREPARING AMINOPYRIMIDINE DERIVATIVES THEREWITH |
| MY201038A (en) * | 2017-07-28 | 2024-01-31 | Yuhan Corp | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same |
| SG11201913517UA (en) * | 2017-07-28 | 2020-02-27 | Yuhan Corp | Improved process for preparing aminopyrimidine derivatives |
| JP6985764B2 (ja) * | 2017-08-30 | 2021-12-22 | 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. | アミノピリミジン系化合物、この化合物を含む組成物およびそれらの使用 |
| CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
| CN108047207A (zh) * | 2018-01-30 | 2018-05-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用 |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| WO2020125391A1 (zh) * | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| PT3943491T (pt) * | 2019-03-19 | 2025-07-28 | Voronoi Inc | Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz |
| CA3133766A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| CN111747950B (zh) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| MX2021013955A (es) * | 2019-05-14 | 2022-03-11 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación. |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| US12138351B2 (en) | 2020-04-14 | 2024-11-12 | Janssen Biotech, Inc. | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| EP4210702A1 (en) | 2020-09-14 | 2023-07-19 | JANSSEN Pharmaceutica NV | Fgfr inhibitor combination therapies |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| TWI867047B (zh) * | 2020-09-18 | 2024-12-21 | 南韓商沃若諾伊公司 | 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物 |
| WO2022131741A1 (ko) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| EP4335847A1 (en) * | 2021-05-07 | 2024-03-13 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| CN115667251A (zh) | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
| WO2022253261A1 (zh) | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
| JP2025510910A (ja) | 2022-03-31 | 2025-04-15 | アストラゼネカ・アクチエボラーグ | 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤 |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| CA3259492A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER |
| KR20250044679A (ko) | 2022-07-08 | 2025-04-01 | 아스트라제네카 아베 | 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제 |
| WO2025017409A1 (en) | 2023-07-14 | 2025-01-23 | Janssen Biotech, Inc. | Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| CN116655600B (zh) * | 2023-05-23 | 2025-08-22 | 江南大学 | 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途 |
| AU2024337472A1 (en) | 2023-09-05 | 2026-04-16 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026009146A1 (en) | 2024-07-01 | 2026-01-08 | Hetero Labs Limited | Benzimidazole compounds as egfr inhibitors |
| WO2026038160A1 (en) | 2024-08-13 | 2026-02-19 | Janssen Biotech, Inc. | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies |
| CA3278557A1 (en) | 2024-08-13 | 2026-03-01 | Janssen Biotech, Inc. | Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
| WO2026047630A1 (en) | 2024-08-31 | 2026-03-05 | Hetero Labs Limited | Heterocyclic compounds as egfr inhibitors |
| WO2026053183A1 (en) | 2024-09-09 | 2026-03-12 | Hetero Labs Limited | Benzothiazole and benzoxazole compounds as egfr inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2280515A1 (en) | 1997-03-11 | 1998-09-17 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| HUP0402106A3 (en) | 2001-11-01 | 2009-07-28 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| JP4428565B2 (ja) | 2004-10-05 | 2010-03-10 | 東京エレクトロン株式会社 | 処理液塗布装置 |
| JP2008515986A (ja) | 2004-10-13 | 2008-05-15 | ワイス | Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物 |
| ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| US20070072894A1 (en) | 2005-03-24 | 2007-03-29 | Kempf J V | Synthesis of pyrroloquinoline quinone (PQQ) |
| JP5007029B2 (ja) | 2005-07-13 | 2012-08-22 | Ｎｔｎ株式会社 | グリース組成物および該グリース封入転がり軸受 |
| KR101011958B1 (ko) | 2005-08-25 | 2011-01-31 | 에프. 호프만-라 로슈 아게 | ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸 |
| JP2007117465A (ja) | 2005-10-28 | 2007-05-17 | Sharp Corp | 集塵器およびそれを備えた電気掃除機 |
| GB2450046B (en) | 2006-03-29 | 2011-03-09 | Kt Freetel Co Ltd | Digital device and method for providing additional service by using the same |
| CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| WO2007120593A1 (en) | 2006-04-12 | 2007-10-25 | Wyeth | Anilino-pyrimidine phenyl and benzothiophene analogs |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| BR112013020641B1 (pt) | 2011-02-25 | 2021-11-03 | Yuhan Corporation | Composto, composição farmacêutica, processos para a preparação de composto e respectivo uso ou de seu sal farmaceuticamente aceitável |
| EP4119551A1 (en) | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| US8871778B2 (en) | 2012-01-20 | 2014-10-28 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| CN104583195B (zh) * | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| ES2792979T3 (es) * | 2013-08-22 | 2020-11-12 | Jubilant Biosys Ltd | Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| WO2015188777A1 (en) * | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| HUE054848T2 (hu) * | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
-
2015
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190B1/en active Active
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 RS RS20260012A patent/RS67623B1/sr unknown
- 2015-10-13 SI SI201532056T patent/SI3929190T1/sl unknown
- 2015-10-13 KR KR1020247013986A patent/KR20240074820A/ko active Pending
- 2015-10-13 LT LTEP24166947.2T patent/LT4421069T/lt unknown
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 MX MX2020002168A patent/MX385942B/es unknown
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 FI FIEP21171619.6T patent/FI3929190T3/fi active
- 2015-10-13 EP EP24166947.2A patent/EP4421069B1/en active Active
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 RS RS20250168A patent/RS66529B1/sr unknown
- 2015-10-13 FI FIEP24166947.2T patent/FI4421069T3/fi active
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 DK DK24166947.2T patent/DK4421069T3/da active
- 2015-10-13 PL PL24166947.2T patent/PL4421069T3/pl unknown
- 2015-10-13 HU HUE21171619A patent/HUE070874T2/hu unknown
- 2015-10-13 SM SM20210266T patent/SMT202100266T1/it unknown
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Active
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 ES ES21171619T patent/ES3009926T3/es active Active
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en not_active Ceased
- 2015-10-13 SI SI201532091T patent/SI4421069T1/sl unknown
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 HR HRP20250213TT patent/HRP20250213T1/hr unknown
- 2015-10-13 PL PL21171619.6T patent/PL3929190T3/pl unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 PT PT211716196T patent/PT3929190T/pt unknown
- 2015-10-13 PT PT241669472T patent/PT4421069T/pt unknown
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active Active
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 EP EP25220748.5A patent/EP4725554A2/en active Pending
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 SM SM20250069T patent/SMT202500069T1/it unknown
- 2015-10-13 ES ES24166947T patent/ES3058882T3/es active Active
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active Active
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 SM SM20250500T patent/SMT202500500T1/it unknown
- 2015-10-13 DK DK21171619.6T patent/DK3929190T3/da active
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 US US14/881,930 patent/US9593098B2/en not_active Ceased
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active Active
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 HR HRP20251702TT patent/HRP20251702T1/hr unknown
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 SM SM20200059T patent/SMT202000059T1/it unknown
- 2015-10-13 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2015-10-13 LT LTEP21171619.6T patent/LT3929190T/lt unknown
-
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
-
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
-
2020
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
-
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown
-
2022
- 2022-11-18 US US18/057,062 patent/USRE50528E1/en active Active
-
2025
- 2025-05-28 NL NL301329C patent/NL301329I2/nl unknown
- 2025-05-30 CY CY2025016C patent/CY2025016I2/el unknown
- 2025-06-02 HU HUS2500023C patent/HUS2500023I1/hu unknown
- 2025-06-03 FR FR25C1021C patent/FR25C1021I2/fr active Active
- 2025-06-03 LT LTPA2025522C patent/LTPA2025522I1/lt unknown
- 2025-06-05 NO NO2025025C patent/NO2025025I1/no unknown
- 2025-06-06 FI FIC20250023C patent/FIC20250023I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500488A1 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| PH12017500196A1 (en) | Cyclohexyl-ethyl substituted diaza - and triaza-tricyclic compounds as indole-amine-2, 3-dioxygenase (ido) antagonists for the treatment of cancer | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| TN2016000560A1 (en) | Heteroaryl compounds for kinase inhibition | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| MY160820A (en) | Kinase inhibitors | |
| MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| EA201790921A1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
| MX2013013294A (es) | Inhibidores de tirosina-cinasas. | |
| WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| MX2016010106A (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| HK1251567A1 (zh) | 用於激酶抑制的杂芳基化合物 | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| NZ763986A (en) | Heteroaryl compounds for kinase inhibition | |
| JOP20160150B1 (ar) | مركبات كينازولين مستبدلة وطرق استعمالها |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2021 BY CPA GLOBAL Effective date: 20200903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2022 BY CPA GLOBAL Effective date: 20210902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2023 BY CPA GLOBAL Effective date: 20220902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2024 BY CPA GLOBAL Effective date: 20230831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240829 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250828 |